Author:
Gentile Massimo,Vigna Ernesto,Palmieri Salvatore,Galli Monica,Derudas Daniele,Mina Roberto,Pepa Roberta Della,Zambello Renato,Martino Enrica Antonia,Bruzzese Antonella,Mangiacavalli Silvia,Zamagni Elena,Califano Catello,Musso Maurizio,Conticello Concetta,Cerchione Claudio,Mele Giuseppe,Di Renzo Nicola,Offidani Massimo,Tarantini Giuseppe,Casaluci Gloria Margiotta,Rago Angela,Ria Roberto,Uccello Giuseppina,Barilà Gregorio,Palumbo Gaetano,Pompa Alessandra,Vincelli Donatella,Brunori Marino,Accardi Fabrizio,Amico Valeria,Amendola Angela,Fontana Raffaele,Bongarzoni Velia,Rossini Bernardo,Cotzia Emilia,Gozzetti Alessandro,Rizzi Rita,Sgherza Nicola,Ferretti Eleonora,Bertuglia Giuseppe,Nappi Davide,Petrucci Maria Teresa,Di Raimondo Francesco,Neri Antonino,Morabito Fortunato,Musto Pellegrino
Abstract
In the ELOQUENT-3 trial, the combination of elotuzumab, pomalidomide and dexamethasone (EloPd) proved a superior clinical benefit over Pd with a manageable toxicity profile, leading to its approval in relapsed/refractory multiple myeloma (RRMM), who had received at least two prior therapies, including lenalidomide and a proteasome inhibitor (PI).
We report here a real-world experience of 200 RRMMs treated with EloPd in 35 Italian centers outside of clinical trials. In our dataset, the median number of prior lines of therapy was 2, with 51% of cases undergoing autologous stem cell transplant (ASCT) and 73% exposed to daratumumab.
After a median follow-up of 9 months, 126 patients stopped EloPd, most of them (88.9%) because of disease progression. The overall response rate (ORR) was 55.4%, in line with the pivotal trial results. Regarding adverse events, our cohort experienced a toxicity profile similar to the ELOQUENT-3 trial, with no significant differences between younger (
Publisher
Ferrata Storti Foundation (Haematologica)
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献